Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer

被引:34
|
作者
Brown, T. [1 ]
Boland, A. [1 ]
Bagust, A. [1 ]
Oyee, J. [1 ]
Hockenhull, J. [1 ]
Dundar, Y. [1 ]
Dickson, R. [1 ]
Ramani, V. S. [1 ]
Proudlove, C. [1 ]
机构
[1] Univ Liverpool, Liverpool Reviews & Implementat Grp, Liverpool L69 3GB, Merseyside, England
关键词
D O I
10.3310/hta14suppl2/10
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in accordance with the licensed indication, based upon the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process. The submitted clinical evidence consisted of the IRESSA Pan-ASian Study (IPASS); a phase III open-label randomised controlled trial conducted in 87 centres in East Asia which compared the use of gefitinib with paclitaxel/carboplatin in 1217 chemotherapy (CTX)-naive patients with stage IIIB/IV pulmonary adenocarcinoma. The manufacturer's submission focused on a subgroup of patients in IPASS who were epidermal growth factor receptor (EGFR) gene mutation-positive (M+) (n = 261; 21% of the total IPASS population). The primary clinical outcome was progression-free survival (PFS). Secondary outcomes included overall survival, clinically relevant improvement in quality of life and adverse events (AEs). Cost-effectiveness was measured in terms of incremental cost per quality-adjusted life-year (QALY). In the overall population, PFS was significantly longer in patients treated with gefitinib than in those treated with paclitaxel/carboplatin (hazard ratio 0.74, 95% confidence interval 0.65 to 0.85; p < 0.0001). The manufacturer reported an incremental cost-effectiveness ratio (ICER) of 20,744 pound per QALY gained for the target population. The probabilistic sensitivity analysis illustrated that for patients who are EGFR M+, gefitinib compared with doublet CTX was not likely to be cost-effective at what would usually be considered standard levels of willingness to pay for an additional QALY; the mean ICER for gefitinib EGFR M+ versus doublet CTX EGFR M+ was reported as 35,700 pound per QALY. Additional analysis by the ERG included amendments to the base-case analysis, including an alternative approach to projecting survival, inclusion of two important additional comparators, sensitivity to EGFR M+ prevalence, and AE costs and disutilities. The manufacturer's submission provides clinical evidence to support the use of gefitinib in EGFR M+ patients with adenocarcinoma histology only. Before patients can be offered first-line treatment with gefitinib they must undergo EGFR mutation status testing which is currently not routinely available in the NHS. At the time of writing, the guidance document issued by NICE on 28 July 2010 states that 'Gefitinib is recommended as an option for the first-line treatment of people with locally advanced or metastatic non-small-cell lung cancer (NSCLC) if they test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and the manufacturer provides gefitinib at the fixed price agreed under the patient access scheme'.
引用
收藏
页码:71 / 79
页数:9
相关论文
共 50 条
  • [21] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
    Matthew K. Wong
    Alvis I. Lo
    Bing Lam
    W. K. Lam
    Mary S. Ip
    James C. Ho
    [J]. Cancer Chemotherapy and Pharmacology, 2010, 65 : 1023 - 1028
  • [22] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
    An, Chaolun
    Zhang, Jiajun
    Chu, Hongjun
    Gu, Chunyan
    Xiao, Feng
    Zhu, Fengwei
    Lu, Rujian
    Shi, Hai
    Zhang, Hongfei
    Yi, Xin
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
  • [23] Quality of life in advanced non-small cell lung cancer patients receiving first-line gefitinib monotherapy
    Shao, Y.
    Lin, Z.
    Hu, F.
    Yu, C.
    Shih, J.
    Hu, W.
    Chang, Y.
    Cheng, A.
    Yang, P.
    Yang, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Treatment of locally advanced and metastatic non-small cell lung cancer in the elderly
    Zimmermann, FB
    Molls, M
    Jeremic, B
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (01) : 203 - +
  • [25] First-line combination immunotherapy for metastatic non-small cell lung cancer
    Chen, Yuh-Min
    [J]. JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (05) : 433 - 441
  • [26] Pembrolizumab for the first-line treatment of non-small cell lung cancer
    Ninomiya, Kiichiro
    Hotta, Katsuyuki
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1015 - 1021
  • [27] First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
    Yin Y.-M.
    Geng Y.-T.
    Shao Y.-F.
    Hu X.-L.
    Li W.
    Shu Y.-Q.
    Wang Z.-X.
    [J]. Journal of Experimental & Clinical Cancer Research, 29 (1)
  • [28] First-Line Single Agent Treatment With Gefitinib in Advanced Non-Small-Cell Lung Cancer Patients
    Yin, Yong-mei
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (05) : 325 - 325
  • [29] Pemetrexed in first-line treatment of non-small cell lung cancer
    Esteban, Emilio
    Casillas, Marta
    Cassinello, Alejo
    [J]. CANCER TREATMENT REVIEWS, 2009, 35 (04) : 364 - 373
  • [30] The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    [J]. CANCERS, 2023, 15 (08)